Literature DB >> 2526818

The influence of gonadal function and the effect of gonadal suppression treatment on final height in growth hormone (GH)-treated GH-deficient children.

I Hibi1, T Tanaka, A Tanae, J Kagawa, N Hashimoto, A Yoshizawa, K Shizume.   

Abstract

One hundred and sixty-one children with idiopathic GH deficiency who received GH treatment were followed until they reached their final height. Final height was found to be influenced by gonadal function. In 108 patients who had spontaneous puberty (91 boys and 17 girls; group A), the mean final height was 151.8 +/- 6.6 (+/- SD) cm in boys and 141.7 +/- 7.4 cm in girls. In 29 patients with combined GH and gonadotropin deficiency (23 boys and 6 girls; group C), whose pubertal development was induced artificially at age 19.5 +/- 2.1 yr in the boys and 18.6 +/- 1.8 yr in the girls, the mean final height was 163.7 +/- 3.9 cm in boys and 151.0 +/- 5.1 cm in girls. The differences in final height between groups A and C were significant in both boys and girls. The shorter final height in group A was caused by the shorter pubertal duration and smaller pubertal height gain than those in normal children. In 24 patients (17 boys and 7 girls; group B) who developed early signs of puberty, gonadal suppression therapy with cyproterone acetate and/or medroxyprogesterone acetate was given. The mean SD score of the final height in these 24 patients was -2.1 +/- 0.6, significantly higher than that in group A. This beneficial effect of gonadal suppression treatment on final height was caused by increases in the duration of puberty and the pubertal height gain.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2526818     DOI: 10.1210/jcem-69-2-221

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Catch-up growth after prolonged hypothyroidism.

Authors:  B Boersma; B J Otten; G B Stoelinga; J M Wit
Journal:  Eur J Pediatr       Date:  1996-05       Impact factor: 3.183

2.  Acquired growth hormone deficiency due to pituitary stalk transection after head trauma in childhood.

Authors:  C Yamanaka; T Momoi; I Fujisawa; K Kikuchi; M Kaji; H Sasaki; T Yorifuji; H Mikawa
Journal:  Eur J Pediatr       Date:  1993-02       Impact factor: 3.183

3.  Failure to improve height prediction in short-stature pubertal adolescents by inhibiting puberty with luteinizing hormone-releasing hormone analogue.

Authors:  D Lindner; J C Job; J L Chaussain
Journal:  Eur J Pediatr       Date:  1993-05       Impact factor: 3.183

4.  Attainment of normal height in severe juvenile hypothyroidism.

Authors:  K Minamitani; A Murata; H Ohnishi; K Wataki; T Yasuda; H Niimi
Journal:  Arch Dis Child       Date:  1994-05       Impact factor: 3.791

Review 5.  Growth hormone deficiency throughout puberty.

Authors:  A Albanese; R Stanhope
Journal:  J Endocrinol Invest       Date:  1992-11       Impact factor: 4.256

6.  A unique case of combined pituitary hormone deficiency caused by a PROP1 gene mutation (R120C) associated with normal height and absent puberty.

Authors:  Armando Arroyo; Flavia Pernasetti; Vyacheslav V Vasilyev; Paula Amato; Samuel S C Yen; Pamela L Mellon
Journal:  Clin Endocrinol (Oxf)       Date:  2002-08       Impact factor: 3.478

Review 7.  Growth hormone treatment in children: review of safety and efficacy.

Authors:  Mark Harris; Paul L Hofman; Wayne S Cutfield
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

8.  Combined Treatment with Gonadotropin-releasing Hormone Analog and Anabolic Steroid Hormone Increased Pubertal Height Gain and Adult Height in Boys with Early Puberty for Height.

Authors:  Toshiaki Tanaka; Yasuhiro Naiki; Reiko Horikawa
Journal:  Clin Pediatr Endocrinol       Date:  2012-03-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.